ISSN : 1301-5680
e-ISSN : 2149-8156
Turkish Journal of Thoracic and Cardiovascular Surgery     
Choice of medication for radial artery vasodilation in patients awaiting coronary artery bypass grafting
Nevzat Erdil1, Vedat Nisanoğlu1, Tamer Eroğlu1, Recep Tüten1, Hasan Berat Cihan1, Ramazan Kutlu2, Bektaş Battaloğlu1, Saim Yoloğlu3
1Departments of Cardiovascular Surgery, Medicine Faculty of İnönü University, Malatya
2Departments of Radiology, Medicine Faculty of İnönü University, Malatya
3Departments of Biostatistics, Medicine Faculty of İnönü University, Malatya

Abstract

Background: In this study, the vasodilatory effects of calcium antagonists and beta-blockers were investigated.

Methods: After obtaining Faculty Ethics Committee approval and written informed consent from the patients, 72 adult patients (50 males, 27 females; mean age 62.9±9.3 years; range 37 to 75 years) who will undergo elective coronary artery bypass grafting (CABG) surgery were included in this study. We evaluated the vasodilatory effect of diltiazem alone (group 1), nifedipine alone (group 2), amlodipine alone (group 3), nebivolol alone (group 4) and nifedipine in combination with metoprolol (group 5). Seventy-seven patients who would undergo isolated CABG using radial artery were prospectively randomized to oral agents four or five days before operation. The dilatation of the lumen diameter and area of the radial artery were evaluated with high-resolution ultrasonography just before and 4-5 days after medical treatment.

Results: Diltiazem alone group (p=0.058) and niphedipine in combination with metoprolol group (p=0.067) did not show a significant increase in the lumen diameter and area after medical treatment compared to the pretreatment values. Statistically significant increases in lumen diameter and area were observed in nifedipine (p=0007), amlodipine (p=0.003) and nebivolol (p=0.047) groups.

Conclusion: Our results demonstrate that calcium channel antagonists are not equally effective in radial artery vasodilatation. Nifedipine, amlodipine and nebivolol appear to be the most effective agents in reducing radial artery spasm. Nebivolol is a betablocker and also has a potent vasodilatory effect on radial ar tery vasospasm.

The radial artery (RA) is increasingly used as a conduit for coronary artery bypass grafting (CABG) due to reports of long-term patency, accessibility, encouraging mid-term results and the need for additional conduits.[1-3] The potential disadvantage of the radial artery is its increased tendency to spasm because of its greater muscular content compared with other arteries.[4,5] Vasodilators such as calcium-channel antagonists, especially diltiazem, may be used to prevent perioperative and postoperative radial artery spasm.[1,6,7]

The use of a potent vasodilator with minimal side effects is an important parameter for the successful use of the radial artery as a conduit in CABG surgery. We investigated and reported the vasodilatory effect of calcium antagonists and beta-blockers in this study.

Methods

Patients
After obtaining Faculty Ethics Committee approval and written informed consent, 72 adult patients (50 males, 27 females; mean age 62.9±9.3 years; range 37 to 75 years) with coronary artery disease who had been admitted to the Department of Cardiothoracic Surgery of Turgut Özal Medical Center for elective CABG were included in this randomized double-blind study. They were divided into five groups; group 1 was treated with diltiazem (90 mg/per day) alone, group 2 was treated with nifedipine (30 mg/per day) alone, group 3 was treated with amlodipine (10 mg/per day) alone, group 4 was treated with nebivolol (5 mg/per day) alone and group 5 was treated with nifedipine (30 mg/per day) in combination with metoprolol (100 mg/per day). They were prospectively randomized to oral agents four or five days before operation. The exclusion criteria included emergent operation, unstable angina and the patients who stopped treatment because of side effects such as hypotension and bradycardia. The demographic data was similar in all groups as seen in table 1. The effect of each drug on the radial artery was evaluated after 4-5 days administration by a blinded evaluator.

Table 1: Patients demographics

Radial artery measurements
An ultrasound device (color Doppler Acuson 128 XP/10 with 7-MHz linear transducer, (Acuson, Mountain View, CA, USA) was used for high-resolution ultrasound measurements and color Doppler images. The measurements of the radial artery lumen diameter were taken before and after drug administration by a blinded evaluator. For each patient, optimal radial artery images were obtained between 2 and 5 cm above the radial styloid. This location was marked, and all images were obtained at the same location.

Statistical methods
All analyses were conducted with SPSS 10.0 software (SPSS Inc, Chicago, Ilinois USA). Continuous variables were presented as mean ± standard deviation; categorical variables were presented as numbers. Normality for continued variables in groups was determined by the Shapiro Wilk test. Because the variables did not show normal distribution (p<0.05), comparisons of groups were performed with the Kruskal-Wallis analysis of variance test and pre-post comparisons with paired observations were analyzed by using the Wilcoxon test. The Fisher's exact test and Pearson Chi-square test were used for comparison of discrete variables between studied groups. In all statistical comparisons the p values <0.05 were reported significant.

Results

The results for the demographic features in the five treatment groups are shown in table 1. There were no statistically significant differences among groups with mean age, mean body surface area, mean body mass index, mean left ventricle end diastolic pressure and left ventricle performance score.

Table 2 summarizes the radial artery diameter before and after treatment (mm) and table 3 summarizes the radial artery cross-sectional area (mm2) before and after treatment. The respective mean pre-treatment and posttreatment RA diameter in each group follows: 3.5±0.7 and 3.6±0.6 mm in the diltiazem group (p=0.058); 3.3±0.7 and 3.6±0.7 mm in the nifedipine group (p=0.007); 3.6±0.6 and 4.0±0.6 mm in the amlodipine group (p=0.003); 4.2±0.8 and 4.5±0.7 mm in the nebivolol group (p=0.047) and 3.0±0.7 and 3.2±0.9 mm in the nifedipine + metaprolol group (p=0.067). The respective mean pre-treatment and post-treatment RA cross-sectional area in each group follows: 0.15±0.22 and 0.16±0.23 mm2 in the diltiazem group (p=0.05); 0.09±0.05 and 0.14±0.13 mm2 in the nifedipine group (p=0.004); 0.11±0.04 and 0.14±0.04 mm2 i n t he a mlodipine group (p=0.002); 0.14±0.06 and 0.17±0.05 mm2 in the nebivolol group (p=0.069) and 0.07±0.03 and 0.08±0.04 mm2 in the nifedipine + metaprolol group (p=0.103).

Table 2: Radial artery diameter before and after treatment (mm)

Table 3: Radial artery cross-sectional area before and after treatment (mm2)

As shown, when compared the radial artery diameter and cross-sectional area before and after the treatment the significant and most increased values were found in nifedipine, amlodipine and nebivolol groups. In diltiazem group the radial artery diameter and cross-sectional area increased but it was not statistically significant. The radial artery diameter and cross-sectional area were increased also in nifedipine + metaprolol group but it was not statistically significant. When compared the results of nifedipine, amlodipine and nebivolol groups there were no differences found.

Discussion

The radial artery is increasingly used as a conduit for CABG due to reports of long-term patency, accessibility, encouraging mid-term results and the need for additional conduits.[1-3] There are also some disadvantages of using the radial artery as a conduit; it is prone to vasospasm in the early postoperative period.[4,8,9] Neurohormonal system activation, which includes elevated endothelin and norepinephrine, occurs after CABG and may contribute to early RA vasospasm.[10-15] The main subject is the choice of vasodilators used on radial conduits.[16-19] In our study we compared the effects of diltiazem, nifedipine, amlodipine, nebivolol and nifedipine + metoprolol for radial artery spasm when used preoperatively. There are three kinds of calcium-channel antagonists which affect voltage-sensitive calcium channels- dihydropyridines, benzothiazepins and phenylalkylamines.[20] Both nifedipine and amlodipine have dihydropyridine rings that may be responsible for their increased vascular selective properties, and this class of calcium channel antagonist also produces less severe effects on myocardial conduction and activation.[20-24] Diltiazem is a 1.5-benzothiazepine that binds to a subunit of L-type calcium channel.[19] L-type blockade in the heart results in negative inotropic and chronotropic effect that induces bradycardia, especially when used with beta-blockers.[17]

Nebivolol is a β1-selective adrenergic receptor antagonist, which is also the precursor of nitric oxide. Nitric oxide is a potent vasodilator which is released from endothelial cells of arteries. Metoprolol is a beta-blocker which can be used for management of ischemic heart failure in combination with calcium channel blockers.

As shown in table 2 and 3, when comparing the radial artery diameter and cross-sectional area before and after treatment the significant and most increased values were found in the nifedipine and amlodipine groups. When comparing the results of nifedipine and amlodipine groups there were no significant differences found. These results were concordant with the results reported in the literature.[20-24]

The radial artery diameter and cross-sectional area were also increased in the nebivolol group and it was statistically significant, with equal increases in radial artery diameter and cross-sectional areas compared with the results of the nifedipine and amlodipine groups. Nebivolol produces vasodilation in the human forearm vascular bed via the L-arginine/nitric oxide pathway.[25] For the peripheral vasodilator effects of nebivolol, prospective and wide studies must be done. Nebivolol can also be used as part of a combined ischemic and hypertension therapy. Metoprolol is a beta-blocker which can be used for management of ischemic heart failure in combination with calcium channel blockers. This was the basis for treating a group of our patients with metoprolol and nifedipine combination. In this group the radial artery diameter and cross-sectional area were increased but it was not statistically significant. Still and all, we can also use nifedipine + metoprolol combination therapy in coronary artery disease patients undergoing CABG without any radial spasmodic side effects.

In the diltiazem group the radial artery diameter and cross-sectional area were also increased but it was not statistically significant. Diltiazem's advantage is its infusion form and today most clinics use diltiazem infusion routinely to prevent perioperative radial artery spasm and cardiac rhythm control.

If the patient populations have preoperative waiting times, the preoperative therapy with these drugs will increase the activity of perioperative and postoperative vasodilator treatment. For the vasodilator treatment of patients who had radial artery as a conduit for CABG we suggest the use of nifedipine and amlodipine from the calcium-channel antagonist group because of their more effective results and nebivolol from the beta-blocker group, which has an unquestionable place in postoperative CABG treatment as an alternative. Further investigations should be done for evaluating the peripheral vasodilator effects in the human forearm vascular bed via the L-arginine/nitric oxide pathway and beta-blocker effects in treatment of patients who had radial artery as a conduit for CABG with a greater number of patients and long treatment period. Although we used nebivolol alone in our study, the combination treatment with nifedipine and amlodipine may have better results.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

References

1) Acar C, Jebara VA, Portoghese M, Beyssen B, Pagny JY, Grare P, et al. Revival of the radial artery for coronary artery bypass grafting. Ann Thorac Surg 1992;54:652-9.

2) Calafiore AM, Teodori G, Di Giammarco G, D'Annunzio E, Angelini R, Vitolla G, et al. Coronary revascularization with the radial artery: new interest for an old conduit. J Card Surg 1995;10:140-6.

3) Buxton B, Fuller J, Gaer J, Liu JJ, Mee J, Sinclair R, et al. The radial artery as a bypass graft. Curr Opin Cardiol 1996;11:591-8.

4) Chester AH, Marchbank AJ, Borland JA, Yacoub MH, Taggart DP. Comparison of the morphologic and vascular reactivity of the proximal and distal radial artery. Ann Thorac Surg 1998;66:1972-6.

5) Nisanoglu V, Battaloglu B, Ozgur B, Eroglu T, Erdil N. Topical vasodilators for preventing radial artery spasm during harvesting for coronary revascularization: comparison of 4 agents. Heart Surg Forum 2006;96:E807-12.

6) Brodman RF, Frame R, Camacho M, Hu E, Chen A, Hollinger I. Routine use of unilateral and bilateral radial arteries for coronary artery bypass graft surgery. J Am Coll Cardiol 1996;28:959-63.

7) Chen AH, Nakao T, Brodman RF, Greenberg M, Charney R, Menegus M. Early postoperative angiographic assessment of radial grafts used for coronary artery bypass grafting. Thorac Cardiovasc Surg 1996;111:1208-12.

8) Fisk RL, Brooks CH, Callaghan JC, Dvorkin J. Experience with the radial artery graft for coronary artery bypass. Ann Thorac Surg 1976;21:513-8.

9) Chiu CJ. Why do radial artery grafts for aortocoronary bypass fail? A reappraisal. Ann Thorac Surg 1976;22:520-3.

10) Dorman BH, Bond BR, Clair MJ, Walker CA, Pinosky ML, Reeves ST, et al. Temporal synthesis and release of endothelin within the systemic and myocardial circulation during and following cardiopulmonary bypass: relation to postoperative recovery [Abstract]. American Heart Association, 71st Annual Scientific Sessions. November 9-12, 1998, Dallas, USA: 1998.

11) Knothe C, Boldt J, Zickmann B, Ballesteros M, Dapper F, Hempelmann G. Endothelin plasma levels in old and young patients during open heart surgery: correlations to cardiopulmonary and endocrinology parameters. J Cardiovasc Pharmacol 1992;20:664-70.

12) Colson P, Grolleau D, Chaptal PA, Ribstein J, Mimran A, Roquefeuil B Chest. Effect of preoperative renin-angiotensin system blockade on hypertension following coronary surgery. Chest 1988;93:1156-8.

13) Matheis G, Haak T, Beyersdorf F, Baretti R, Polywka C, Winkelmann BR. Circulating endothelin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 1995;9:269-74.

14) Chardigny C, Jebara VA, Acar C, Descombes JJ, Verbeuren TJ, Carpentier A, et al. Vasoreactivity of the radial artery. Comparison with the internal mammary and gastroepiploic arteries with implications for coronary artery surgery. Circulation 1993;88:II115-27.

15) He GW, Yang CQ. Radial artery has higher receptor-mediated contractility but similar endothelial function compared with mammary artery. Ann Thorac Surg 1997;63:1346-52.

16) Bond BR, Zellner JL, Dorman BH, Multani MM, Kratz JM, Crumbley AJ 3rd, et al. Differential effects of calcium channel antagonists in the amelioration of radial artery vasospasm. Ann Thorac Surg 2000;69:1035-40.

17) He GW, Yang CQ. Comparative study on calcium channel antagonists in the human radial artery: clinical implications. J Thorac Cardiovasc Surg 2000;119:94-100.

18) Shapira OM, Xu A, Vita JA, Aldea GS, Shah N, Shemin RJ, et al. Nitroglycerin is superior to diltiazem as a coronary bypass conduit vasodilator. J Thorac Cardiovasc Surg 1999;117:906-11.

19) Shapira OM, Alkon JD, Macron DS, Keaney JF Jr, Vita JA, Aldea GS, et al. Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm. Ann Thorac Surg 2000;70:883-8.

20) Ferrari R. Major differences among the three classes of calcium antagonists. Eur Heart J 1997;18 Suppl A:A56-70.

21) van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: pharmacological aspects. J Hypertens Suppl 1993;11:S3-11.

22) Burges RA, Dodd MG, Gardiner DG. Pharmacologic profile of amlodipine. Am J Cardiol 1989;64:10I-18I.

23) O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 1998;82:881-7.

24) Resnekov L, Messerli FH, Aepfelbacher FC. Nifedipine. In: Messerli FH, editor. Cardiovascular drug therapy. 2nd ed. Philadelphia: W.B. Saunders Company; 1996. p. 972.

25) Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.

Keywords : Coronary artery bypass grafting; hypertension/etiology; nitric oxide; radial artery
Viewed : 16269
Downloaded : 3702